Department of Oncology, Oxford Cancer Center, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, OX3 7LE, Oxford, UK.
Department of Oncology, University of Oxford, OX3 7ER, Oxford, UK.
Immunotherapy. 2024 Mar;16(4):257-266. doi: 10.2217/imt-2022-0277. Epub 2024 Jan 10.
Triple-negative breast cancer (TNBC) comprises 15-20% of all breast cancers (BC). Lacking targeted therapy options, TNBC becomes the focal point of clinical investigations aiming not only to identify drugs with enhanced response potential but also to uncover new immunological and/or metabolic pathways conducive to more effective treatments. Currently, neoadjuvant treatment for TNBC relies on standard chemotherapy in conjunction with immunotherapy, given the improved response observed with this drug combination. This review delves into the latest therapeutic updates in TNBC treatment and explores potential advancements shaping the future landscape of this disease in the neoadjuvant setting.
三阴性乳腺癌（TNBC）占所有乳腺癌（BC）的 15-20%。由于缺乏靶向治疗选择，TNBC 成为临床研究的焦点，不仅旨在确定具有增强反应潜力的药物，还旨在发现新的免疫和/或代谢途径，以实现更有效的治疗。目前，由于观察到这种药物组合的反应改善，TNBC 的新辅助治疗依赖于标准化疗联合免疫疗法。本文深入探讨了 TNBC 治疗的最新治疗进展，并探讨了可能塑造新辅助治疗中这种疾病未来格局的潜在进展。
